Sorrento Therpt (SRNE)

$2.75 0.02 (0.54%)

11:38 EDT SRNE Stock Quote Delayed 30 Minutes

10 Stocks to Sell Before They Die

By Thomas Yeung, CFA, InvestorPlace Markets Analyst Jul 29, 2022

As the U.S. continues to struggle with stagflation, it’s becoming more important than ever to avoid pitfalls.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Dear SRNE Stock Fans, Here’s the Latest Patent News to Watch

7 Biotech Stocks to Buy Amid the Delta Variant’s Onslaught

Volume:

Previous Close -

Market Cap 939.71M

PE Ratio -1.92

EPS -1.43

Volume (Avg. Vol.) 3.60M

Day's Range $2.73 - $2.95

52-Week Range $1.15 - $9.63

Dividend & Yield N/A (N/A)

SRNE Stock Predictions, Articles, and Sorrento Therpt News

From InvestorPlace
From the Web

7 Meme Stocks That You Shouldn’t Touch With a 10-Foot Pole

By Chris Markoch Jul 27, 2021

Not all meme stocks are "bad." But with retail investors beginning to realize the heavy lift that awaits them, you should avoid these seven.

Midday Market Update: What Are the Top Performing Stocks Today?

By William White, InvestorPlace Writer Jul 21, 2021

We're over halfway through the day and that means it's time to check in on what the top-performing stocks are doing on Wednesday.

7 High-Risk, High-Reward Stocks to Buy If You Have an Iron-Clad Stomach

By Josh Enomoto, InvestorPlace Contributor Jun 18, 2021

Although many indicators suggest the market is stretched, if you want to live dangerously, consider these high-risk, high-reward stocks.

7 Meme Stocks to Avoid So You Don’t Get Caught Holding the Bag

By Faizan Farooque Jun 17, 2021

Meme stocks continue to be a thing, despite confounding analysts who are questioning whether they can survive on Reddit steam alone.

SRNE Stock: The Big News Lifting Sorrento Therapeutics Today

By Chris MacDonald, InvestorPlace Contributor Jun 14, 2021

Today, SRNE stock is on the move in a big way as investors price in two key announcements made by the company regarding clinical trials.

7 Former Pandemic Stocks to Buy That Are No Longer Running Hot

By Josh Enomoto, InvestorPlace Contributor May 26, 2021

The pandemic bolstered many stocks to buy. But with cases fading, this narrative is now questionable. These seven stocks require caution.

7 Pharmaceutical Stocks That Could Get a Covid Hangover

By Alex Sirois Apr 1, 2021

Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now.

Take Your Profits! 7 Covid Winners to Sell Now

By Josh Enomoto, InvestorPlace Contributor Mar 23, 2021

Because of the pandemic, many so-called Covid stocks enjoyed outsized gains but investors might want to consider trimming their exposure.

The Dip Is an Opportunity in Sorrento Therapeutics Stock

By InvestorPlace Research Staff Mar 10, 2021

The pullback in SRNE stock has cleared 40%. Sorrento has too many ways to win for the stock to stay down forever.

Sorrento Therapeutics Is Betting On A Longer Play, So Should You

By Louis Navellier and the InvestorPlace Research Staff Mar 9, 2021

The delay of Sorrento Therapeutics’ Covid-19 vaccine has weakened SRNE stock, but the company has plenty more in the pipeline.

Sorrento Stock Is Little More Than a Day Trade Now

By Ian Bezek, InvestorPlace Contributor Dec 21, 2020

Nearly a third of SRNE stock's float has been sold short. This sets up a catalyst for a short-term move, but avoid a long-term investment.

Government and Institutional Support Are Positives for Sorrento Stock

By Larry Ramer, InvestorPlace Contributor Dec 10, 2020

Sorrento just received a grant of up to $34 million from Washington, while multiple institutions own meaningful amounts of SRNE stock.

SRNE Stock: California Testing Approval Stokes Sorrento Therapeutics

By Robert Lakin, InvestorPlace Contributor Dec 9, 2020

Sorrento Therapeutics is poised to roll out clinical testing trials in California. SRNE stock is up in pre-market trading on Wednesday as the country continues to post record Covid-19 diagnoses and hospitalizations.

Sorrento Therapeutics Remains a Buy Between $6 and $6.50

By Will Ashworth, InvestorPlace Contributor Dec 7, 2020

Sorrento Therapeutics has seen SRNE stock close between $5.76 and $8.20 in the past month. Here’s why it’s time for investors to be careful.

Covid-19 Vaccine Makers Still Make Sense, Including Sorrento Therapeutics

By Chris Lau, InvestorPlace Contributor Dec 7, 2020

SRNE stock fell out of favor as bigger vaccine developers grabbed the headlines but that may change soon.

Don’t Chase the Rebound in Sorrento — It’s Not Worth the Risk

By Thomas Niel Dec 4, 2020

SRNE stock may be bouncing back, but given its grab bag of issues, skip out on this fading coronavirus play.

The Shock and Awe of Sorrento Therapeutics Is Long Gone

By Chris Markoch Dec 4, 2020

Sorrento Therapeutics was an early pandemic winner. But as the world closes in on multiple vaccines, SRNE stock looks to be too late.

Hopefuls Back Sorrento Therapeutics But Time Is a Factor

By Larry Sullivan, InvestorPlace contributor Dec 4, 2020

Investors seeking a longshot coronavirus play continue to eye SRNE stock despite Sorrento Therapeutics' high risk and continued volatility.

Sorrento Stock Doesn’t Offer Any Upside as Vaccine Frontrunners Emerge

By Faizan Farooque Dec 2, 2020

The Covid-19 race is close to ending. It seems unlikely that Sorrento stock can pull a rabbit out of a hat with the frontrunners emerging.

Windows of Opportunity Are Tightening for Sorrento Therapeutics

By Josh Enomoto, InvestorPlace Contributor Nov 30, 2020

Thanks to Sorrento Therapeutics’ all-out pivot to address the Covid-19 pandemic, SRNE stock initially became one of the most popular investments. But as both the vaccine and treatment race tighten, the risks multiply.